Who are we?
Established in 2002, Pharmalogic is a privately held Israeli company with expertise in identifying, registering, importing, marketing and selling pharmaceutical products for the Israeli market.
Pharmalogic represents several well known European companies such as: Panpharma, Hermes, Lipomed, and Ever Pharma.
The company’s main business is injectable products mostly cytotoxics and antibiotics. Pharmalogic products are distributed by S.L.E.
The managers of Pharmalogic possess large, in depth knowledge of the Israeli pharmaceutical market. The company holds long standing working relationships with the Ministry of Health and Israeli national HMOs, as well as strong ties with its major clients and the local medical community. The company has a proven track record and is considered to be a valuable partner by the companies it represents.
The company complies with all required guidelines and regulations of the Israeli Ministry of Health as well as international standards.
Pharmalogic aim is to supply high quality pharmaceutical products to the Israeli market.
Drugs Disributed by Pharmalogic Ltd
Alkylating Agent. Dacarbazine 200 mg/vial. VIALS (pwdr. for reconstit.): 1 x 200 mg +
19.7 ml water. I.V. inject.,/infus.
Monother: 4-5 day cycles of 150-250
mg/m² bdy surface/day. May repeat
every 21 days. Alt. tmt: 2.0-4.5 mg/kg/
day for 1-10 days. Can repeat every 28 days. Inject over ±1 min/infus. over
15-30 mins. If necess. may be given I.A.
Comb. chemother: 4-5 day cycles of
100 mg/m²/day with 21 day intervals
start. from last day tmt.
Metastat. malign. melanoma, Hodgkin’s
dis. as 2nd line ther. when used in comb.
with other agents.
C/I: Hypersens., ren. insuffic., bone
marrow defic., pregn., lact.
Pyrimidine Analogues. Gemcitabine (HCl) 4 mg/ml. VIAL (conc. for sol. for infus.): 1 x 200 mg
x 40 mg/ml; 1 x 1,000 mg x 40 mg/ml.
I.V. Adjust. accord. indicats, gen. cond.,
hepat./ren. funct., concur. chemother.,
bl. counts. See lit.
Pall. tmt in local. advanced/ metastat.
NSCLC, local. advanced/metastat.
adenocarcinoma pancreas, 5-FU refract.
pancreat. cancer, bladder cancer at invas.
stage. In combinat. with paclitaxel for tmt
pts. with unresect. local. recur./metastat.
breast cancer who have relapsed follow.
adjuv./neoadjuv. chemother. Prior
chemother. should have included
anthracycline unless C/I. In comb. with
carboplatin for recur. epithelial ovarian
carcinoma that has relapsed at least 6
mths aft. platinum based ther.
C/I: Hypersens., pregn., lact. See lit.
Anticoagulant. Heparin 25,000 IU / 5 ml. VIALS: 25 x 5 ml. I.V./S.C.
See lit.
Thrombo-embol. disords., proph. deep
vein thromb., thrombo-embol. events.
Corticosteroid. Hydrocortisone (as sodium sucinate) 100 mg/dose. VIALS: 25, 100 x 100 mg. I.V./I.M. Dosage
range: 100-500 mg depend. on severity
of cond. See lit.
Conds. respond. to corticoster. ther.
Antimetabolite (purine analog). Cladribine 10 mg / 5 ml. VIALS: 1,5. HCL: S.C: 0.14 mg/kg bdy wt/
day (5.6 mg/m2/day) for 5 consec. days.
I.V. (Contin. infus.): Single course for 7
consec. days: 0.09 mg/kg/day (3.6 mg/
m2/day). CLL: S.C: 0.1 mg/kg bdy wt/
day for 5 consec. days (4.0 mg/ m2/
day). I.V: 2 hrs. on days 1-5 of 28 day
cycle at dose of 0.10 mg/kg/day (4.0
mg/m2 /day). Determine pt. response
every 2 cycles of tmt. In respond. pts.
(lymphocyt. reduct. of 50% or more)
repeat for 2 cycles. In non-respond.
pts. discont. aft. 2 cycles.
Hairy cell leuk. (HCL), chronic lymphocyt.
leuk.(CLL), second line tmt. low grade
Non-Hodgkins lymphoma (NHL).
Oxytocic Agent. Oxytocin 10 IU/ml. AMPS: 10 x 1 ml. See lit.
Induct. labour for medical reasons,
stimulat. labour in hypoton. uterine inertia, during cesar. sect. foll. delivery,
prevent. tmt. post. partum uterine atony
and hemorrh., early stages pregn. as
adjunct. ther. for manage. incomplete,
inevitable or missed abort.
C/I: Hypersens. See lit.
